학술논문
Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients
Document Type
article
Author
Isabel Pérez-Flores; Ignacio Juarez; Arianne S. Aiffil Meneses; Ana Lopez-Gomez; Natividad Calvo Romero; Beatriz Rodriguez-Cubillo; María Angeles Moreno de la Higuera; Belen Peix-Jiménez; Raquel Gonzalez-Garcia; Elvira Baos-Muñoz; Ana Arribi Vilela; Manuel Gómez Del Moral; Eduardo Martínez-Naves; Ana Isabel Sanchez-Fructuoso
Source
Frontiers in Immunology, Vol 14 (2023)
Subject
Language
English
ISSN
1664-3224
Abstract
BackgroundImmunocompromised patients have an increased risk of developing severe COVID disease, as well as a tendency to suboptimal responses to vaccines. The objective of this study was to evaluate the specific cellular and humoral adaptive immune responses of a cohort of kidney transplant recipients (KTR) after 3 doses of mRNA-1273 vaccine and to determinate the main factors involved.MethodsProspective observational study in 221 KTR (149 non infected), 55 healthy volunteers (HV) and 23 dialysis patients (DP). We evaluated anti-spike (by quantitative chemiluminescence immunoassay) and anti-nucleocapsid IgG (ELISA), percentage of TCD4+ and TCD8+ lymphocytes producing IFNγ against S-protein by intracellular flow cytometry after Spike-specific 15-mer peptide stimulation and serum neutralizing activity (competitive ELISA) at baseline and after vaccination.ResultsAmong COVID-19 naïve KTR, 54.2% developed cellular and humoral response after the third dose (vs 100% in DP and 91.7% in HV), 18% only showed cell-mediated response, 22.2% exclusively antibody response and 5.6% none. A correlation of neutralizing activity with both the IgG titer (r=0.485, p1000/mm3 [4.68 (1.72-12.73, p=0.003], eGFR>30 mL/min [7.34(2.72-19.84), p